Australia's most trusted
source of pharma news
Thursday, 05 December 2024
Posted August 1 2022 AM
After just two months in the top job Biogen's new Managing Director David Henderson has clocked up a double PBS win.
Spinal Muscular Atrophy (SMA) drug Spinraza has been expanded to a new patient population while the company's oral treatment for relapsing remitting multiple sclerosis (RRMS), Vumerity has also won a PBS berth.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.